"The reduction in revenue due to Zyprexa patent expirations is expected to be partially offset by growth in key franchises including Cymbalta, Cialis®, Humalog®, Humulin® and Forteo®, as well as continued growth of newer products such as Effient®, Axiron® and Tradjenta®."
this implies that Axiron will be a material contributor to group revenue growth.
pretty awesome to be mentioned in the same sentence as blockbuster names like cymbalta and cialis!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
-0.001(5.56%) |
Mkt cap ! $6.931M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.9¢ | 1.7¢ | $8.809K | 495.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 266679 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 252359 | 2 |
View Market Depth
| Last trade - 14.49pm 24/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |